Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1

Julio C. Ricarte-Filho, Mabel Ryder, Dhananjay A. Chitale, Michael Rivera, Adriana Heguy, Marc Ladanyi, Manickam Janakiraman, David Solit, Jeffrey A. Knauf, R. Michael Tuttle, Ronald A. Ghossein, James A. Fagin

Research output: Contribution to journalArticle

348 Citations (Scopus)

Abstract

Patients with poorly differentiated thyroid cancers (PDTC), anaplastic thyroid cancers (ATC), and radioactive iodinerefractory (RAIR) differentiated thyroid cancers have a high mortality, particularly if positive on [ 18F]fluorodeoxyglucose (FDG)-positron emission tomography (PET). To obtain comprehensive genetic information on advanced thyroid cancers, we designed an assay panel for mass spectrometry genotyping encompassing the most significant oncogenes in this disease: 111 mutations in RET, BRAF, NRAS, HRAS, KRAS, PIK3CA, AKT1, and other related genes were surveyed in 31 cell lines, 52 primary tumors (34 PDTC and 18 ATC), and 55 RAIR, FDG-PET-positive recurrences and metastases (nodal and distant) from 42 patients. RAS mutations were more prevalent than BRAF (44 versus 12%; P = 0.002) in primary PDTC, whereas BRAF was more common than RAS (39 versus 13%; P = 0.04) in PET-positive metastatic PDTC. BRAF mutations were highly prevalent in ATC (44%) and in metastatic tumors from RAIR PTC patients (95%). Among patients with multiple metastases, 9 of 10 showed between-sample concordance for BRAF or RAS mutations. By contrast, 5 of 6 patients were discordant for mutations of PIK3CA or AKT1. AKT1-G49A was found in 9 specimens, exclusively in metastases. This is the first documentation of AKT1 mutation in thyroid cancer. Thus, RAIR, FDG-PET-positive metastases are enriched for BRAF mutations. If BRAF is mutated in the primary, it is likely that the metastases will harbor the defect. By contrast, absence of PIK3CA/AKT1 mutations in one specimen may not reflect the status at other sites because these mutations arise during progression, an important consideration for therapies directed at phosphoinositide 3-kinase effectors.

Original languageEnglish (US)
Pages (from-to)4885-4893
Number of pages9
JournalCancer Research
Volume69
Issue number11
DOIs
StatePublished - Jun 1 2009
Externally publishedYes

Fingerprint

Thyroid Neoplasms
Iodine
Mutation
Positron-Emission Tomography
Neoplasm Metastasis
Factor IX
1-Phosphatidylinositol 4-Kinase
Fluorodeoxyglucose F18
Oncogenes
Documentation
Mass Spectrometry
Neoplasms
Recurrence
Cell Line
Mortality
Genes

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. / Ricarte-Filho, Julio C.; Ryder, Mabel; Chitale, Dhananjay A.; Rivera, Michael; Heguy, Adriana; Ladanyi, Marc; Janakiraman, Manickam; Solit, David; Knauf, Jeffrey A.; Tuttle, R. Michael; Ghossein, Ronald A.; Fagin, James A.

In: Cancer Research, Vol. 69, No. 11, 01.06.2009, p. 4885-4893.

Research output: Contribution to journalArticle

Ricarte-Filho, JC, Ryder, M, Chitale, DA, Rivera, M, Heguy, A, Ladanyi, M, Janakiraman, M, Solit, D, Knauf, JA, Tuttle, RM, Ghossein, RA & Fagin, JA 2009, 'Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1', Cancer Research, vol. 69, no. 11, pp. 4885-4893. https://doi.org/10.1158/0008-5472.CAN-09-0727
Ricarte-Filho, Julio C. ; Ryder, Mabel ; Chitale, Dhananjay A. ; Rivera, Michael ; Heguy, Adriana ; Ladanyi, Marc ; Janakiraman, Manickam ; Solit, David ; Knauf, Jeffrey A. ; Tuttle, R. Michael ; Ghossein, Ronald A. ; Fagin, James A. / Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. In: Cancer Research. 2009 ; Vol. 69, No. 11. pp. 4885-4893.
@article{0ac86cdca1054e6a98d2f8669fd79fab,
title = "Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1",
abstract = "Patients with poorly differentiated thyroid cancers (PDTC), anaplastic thyroid cancers (ATC), and radioactive iodinerefractory (RAIR) differentiated thyroid cancers have a high mortality, particularly if positive on [ 18F]fluorodeoxyglucose (FDG)-positron emission tomography (PET). To obtain comprehensive genetic information on advanced thyroid cancers, we designed an assay panel for mass spectrometry genotyping encompassing the most significant oncogenes in this disease: 111 mutations in RET, BRAF, NRAS, HRAS, KRAS, PIK3CA, AKT1, and other related genes were surveyed in 31 cell lines, 52 primary tumors (34 PDTC and 18 ATC), and 55 RAIR, FDG-PET-positive recurrences and metastases (nodal and distant) from 42 patients. RAS mutations were more prevalent than BRAF (44 versus 12{\%}; P = 0.002) in primary PDTC, whereas BRAF was more common than RAS (39 versus 13{\%}; P = 0.04) in PET-positive metastatic PDTC. BRAF mutations were highly prevalent in ATC (44{\%}) and in metastatic tumors from RAIR PTC patients (95{\%}). Among patients with multiple metastases, 9 of 10 showed between-sample concordance for BRAF or RAS mutations. By contrast, 5 of 6 patients were discordant for mutations of PIK3CA or AKT1. AKT1-G49A was found in 9 specimens, exclusively in metastases. This is the first documentation of AKT1 mutation in thyroid cancer. Thus, RAIR, FDG-PET-positive metastases are enriched for BRAF mutations. If BRAF is mutated in the primary, it is likely that the metastases will harbor the defect. By contrast, absence of PIK3CA/AKT1 mutations in one specimen may not reflect the status at other sites because these mutations arise during progression, an important consideration for therapies directed at phosphoinositide 3-kinase effectors.",
author = "Ricarte-Filho, {Julio C.} and Mabel Ryder and Chitale, {Dhananjay A.} and Michael Rivera and Adriana Heguy and Marc Ladanyi and Manickam Janakiraman and David Solit and Knauf, {Jeffrey A.} and Tuttle, {R. Michael} and Ghossein, {Ronald A.} and Fagin, {James A.}",
year = "2009",
month = "6",
day = "1",
doi = "10.1158/0008-5472.CAN-09-0727",
language = "English (US)",
volume = "69",
pages = "4885--4893",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "11",

}

TY - JOUR

T1 - Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1

AU - Ricarte-Filho, Julio C.

AU - Ryder, Mabel

AU - Chitale, Dhananjay A.

AU - Rivera, Michael

AU - Heguy, Adriana

AU - Ladanyi, Marc

AU - Janakiraman, Manickam

AU - Solit, David

AU - Knauf, Jeffrey A.

AU - Tuttle, R. Michael

AU - Ghossein, Ronald A.

AU - Fagin, James A.

PY - 2009/6/1

Y1 - 2009/6/1

N2 - Patients with poorly differentiated thyroid cancers (PDTC), anaplastic thyroid cancers (ATC), and radioactive iodinerefractory (RAIR) differentiated thyroid cancers have a high mortality, particularly if positive on [ 18F]fluorodeoxyglucose (FDG)-positron emission tomography (PET). To obtain comprehensive genetic information on advanced thyroid cancers, we designed an assay panel for mass spectrometry genotyping encompassing the most significant oncogenes in this disease: 111 mutations in RET, BRAF, NRAS, HRAS, KRAS, PIK3CA, AKT1, and other related genes were surveyed in 31 cell lines, 52 primary tumors (34 PDTC and 18 ATC), and 55 RAIR, FDG-PET-positive recurrences and metastases (nodal and distant) from 42 patients. RAS mutations were more prevalent than BRAF (44 versus 12%; P = 0.002) in primary PDTC, whereas BRAF was more common than RAS (39 versus 13%; P = 0.04) in PET-positive metastatic PDTC. BRAF mutations were highly prevalent in ATC (44%) and in metastatic tumors from RAIR PTC patients (95%). Among patients with multiple metastases, 9 of 10 showed between-sample concordance for BRAF or RAS mutations. By contrast, 5 of 6 patients were discordant for mutations of PIK3CA or AKT1. AKT1-G49A was found in 9 specimens, exclusively in metastases. This is the first documentation of AKT1 mutation in thyroid cancer. Thus, RAIR, FDG-PET-positive metastases are enriched for BRAF mutations. If BRAF is mutated in the primary, it is likely that the metastases will harbor the defect. By contrast, absence of PIK3CA/AKT1 mutations in one specimen may not reflect the status at other sites because these mutations arise during progression, an important consideration for therapies directed at phosphoinositide 3-kinase effectors.

AB - Patients with poorly differentiated thyroid cancers (PDTC), anaplastic thyroid cancers (ATC), and radioactive iodinerefractory (RAIR) differentiated thyroid cancers have a high mortality, particularly if positive on [ 18F]fluorodeoxyglucose (FDG)-positron emission tomography (PET). To obtain comprehensive genetic information on advanced thyroid cancers, we designed an assay panel for mass spectrometry genotyping encompassing the most significant oncogenes in this disease: 111 mutations in RET, BRAF, NRAS, HRAS, KRAS, PIK3CA, AKT1, and other related genes were surveyed in 31 cell lines, 52 primary tumors (34 PDTC and 18 ATC), and 55 RAIR, FDG-PET-positive recurrences and metastases (nodal and distant) from 42 patients. RAS mutations were more prevalent than BRAF (44 versus 12%; P = 0.002) in primary PDTC, whereas BRAF was more common than RAS (39 versus 13%; P = 0.04) in PET-positive metastatic PDTC. BRAF mutations were highly prevalent in ATC (44%) and in metastatic tumors from RAIR PTC patients (95%). Among patients with multiple metastases, 9 of 10 showed between-sample concordance for BRAF or RAS mutations. By contrast, 5 of 6 patients were discordant for mutations of PIK3CA or AKT1. AKT1-G49A was found in 9 specimens, exclusively in metastases. This is the first documentation of AKT1 mutation in thyroid cancer. Thus, RAIR, FDG-PET-positive metastases are enriched for BRAF mutations. If BRAF is mutated in the primary, it is likely that the metastases will harbor the defect. By contrast, absence of PIK3CA/AKT1 mutations in one specimen may not reflect the status at other sites because these mutations arise during progression, an important consideration for therapies directed at phosphoinositide 3-kinase effectors.

UR - http://www.scopus.com/inward/record.url?scp=66349098309&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=66349098309&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-09-0727

DO - 10.1158/0008-5472.CAN-09-0727

M3 - Article

C2 - 19487299

AN - SCOPUS:66349098309

VL - 69

SP - 4885

EP - 4893

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 11

ER -